Palvella Therapeutics Inc... (PVLA)
NASDAQ: PVLA
· Real-Time Price · USD
47.12
1.02 (2.21%)
At close: Aug 15, 2025, 3:59 PM
48.00
1.88%
After-hours: Aug 15, 2025, 05:20 PM EDT
Palvella Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | 53K | 1.3M | 19.52M | 20.05M | 1.94M | 5.85M | 5.37M | 3.7M | 10.99M | 8.44M | 4.06M | 3.29M | 15.63M |
Cost of Revenue | n/a | n/a | n/a | n/a | -30K | n/a | 739K | 725K | 571K | 585K | 772K | 573K | 840K | 588K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | 18.78M | 19.33M | n/a | 5.26M | 4.6M | 3.13M | 10.15M | 7.86M | n/a | n/a | n/a |
Operating Income | n/a | -7.87M | -3.13M | -4.18M | -1.76M | -12.48M | 3.09M | 2.06M | -4.54M | -11.52M | -12.17M | -12.33M | -7.46M | -11M | -19.01M | -16.76M | -5.06M |
Interest Income | n/a | 752K | 169K | 201K | 86K | 455K | 549K | 490K | 357K | 351K | 241K | 132K | n/a | n/a | 4K | 3K | 3K |
Pretax Income | -9.47M | -8.19M | -2.89M | -3.59M | -2.54M | 32.18M | -10.75M | 3.98M | -6.71M | -8.1M | -9.74M | -10.34M | -5.1M | -9.53M | -16.54M | -15.5M | -4.17M |
Net Income | -9.47M | -8.19M | -2.89M | -3.59M | -2.54M | -4.58M | -10.75M | 3.98M | -6.71M | -8.1M | -9.74M | -10.34M | -5.1M | -9.53M | -16.54M | -15.5M | -4.17M |
Selling & General & Admin | 4.13M | 3.8M | 3.58M | 3.43M | 775K | 2.33M | 6.1M | 3.7M | 924K | 3.98M | 3.94M | 4.09M | 4.38M | 4.11M | 4.15M | 4.27M | 4.16M |
Research & Development | 5.12M | 4.07M | -446K | 751K | 984K | 4.45M | 9.6M | 13.57M | 3.62M | 12.8M | 12.82M | 11.36M | 13.22M | 14.75M | 18.33M | 15.18M | 15.94M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 9.25M | 7.87M | 3.13M | 4.18M | 1.76M | 6.78M | 15.7M | 17.27M | 16.88M | 16.78M | 16.77M | 15.46M | 17.61M | 18.85M | 22.48M | 19.45M | 20.09M |
Interest Expense | -1.35M | 1.22M | n/a | n/a | 805K | n/a | n/a | n/a | 2.58M | n/a | n/a | n/a | 3K | 6K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 7.87M | 3.13M | 4.18M | 1.76M | 6.78M | 16.43M | 17.99M | 4.54M | 17.36M | -17.54M | -16.03M | 18.45M | 19.44M | -23.07M | -20.05M | -20.69M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 11.05M | 2.23M | 1.32M | 1.3M | 1.27M | 1.24M | 1.24M | 1.09M | 11.22M | 930.74K | 929.96K | 926.56K | 921.39K | 902.78K | 846.63K | 773.81K | 703.71K |
Shares Outstanding (Diluted) | 11.05M | 2.23M | 1.32M | 1.3M | 1.27M | 1.24M | 1.24M | 1.1M | 11.22M | 930.74K | 929.96K | 926.56K | 921.39K | 902.78K | 846.63K | 773.81K | 703.71K |
EPS (Basic) | -0.86 | -3.68 | -2.19 | -2.76 | -2 | -3.71 | -8.7 | 3.63 | -0.62 | -8.7 | -10.47 | -11.16 | -5.54 | -10.56 | -19.53 | -20.03 | -5.93 |
EPS (Diluted) | -0.86 | -3.68 | -2.19 | -2.76 | -2 | -3.71 | -8.7 | 3.62 | -0.62 | -8.7 | -10.47 | -11.16 | -5.54 | -10.56 | -19.53 | -20.03 | -5.93 |
EBITDA | n/a | -6.97M | -2.89M | -3.59M | -1.73M | -4.58M | -10.01M | 4.7M | -4.13M | -7.52M | -8.96M | -9.77M | -4.26M | -8.94M | -15.95M | -14.9M | -3.57M |
EBIT | n/a | -6.97M | -2.89M | -3.59M | -1.73M | -4.58M | -10.75M | 3.98M | -4.13M | -8.1M | -9.74M | -10.34M | -5.1M | -9.53M | -16.54M | -15.5M | -4.17M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | 739K | 725K | 571K | 585K | 772K | 573K | 840K | 588K | 586K | 594K | 600K |